{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Medications that may NOT be administered', 'No other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy (Hormone', 'replacement therapy (HRT) is acceptable), radiotherapy, biological therapy or other novel', 'agent) is to be permitted while the patient is receiving study medication.', 'Live virus and live bacterial vaccines should not be administered whilst the patient is', 'receiving study medication and during the 30 day follow up period. An increased risk of', 'infection by the administration of live virus and bacterial vaccines has been observed with', 'conventional chemotherapy drugs and the effects with olaparib are unknown.', 'Restricted concomitant medications', 'Strong or Moderate CYP3A inhibitors', 'Known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, boosted', 'protease inhibitors, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate', 'CYP3A inhibitors (ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) should not', 'be taken with olaparib.', 'If there is no suitable alternative concomitant medication then the dose of olaparib should be', 'reduced for the period of concomitant administration. The dose reduction of olaparib should', 'be recorded in the eCRF with the reason documented as concomitant CYP3A inhibitor use.', 'Strong CYP3A inhibitors - reduce the dose of olaparib to 100mg bd for the duration of', 'concomitant therapy with the strong inhibitor and for 5 half lives afterwards.', 'Moderate CYP3A inhibitors - reduce the dose of olaparib to 150mg bd for the duration', 'of concomitant therapy with the moderate inhibitor and for 3 half lives afterwards.', 'After the washout of the inhibitor is complete, the olaparib dose can be re-escalated.', 'Strong or Moderate CYP3A inducers', 'Strong (e.g., phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine,', \"nevirapine, enzalutamide and St John's Wort) and moderate CYP3A inducers (eg. bosentan,\", 'efavirenz, modafinil) of CYP3A should not be taken with olaparib.', 'If the use of any strong or moderate CYP3A inducers are considered necessary for the', \"patient's safety and welfare this could diminish the clinical efficacy of olaparib.\", 'If a patient requires use of a strong or moderate CYP3A inducer or inhibitor then they must be', 'monitored carefully for any change in efficacy of olaparib.', 'P-gp inhibitors', 'It is possible that co-administration of P-gp inhibitors (eg amiodarone, azithromycin) may', 'increase exposure to olaparib. Caution should therefore be observed.', '67(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Effect of olaparib on other drugs', 'Based on limited in vitro data, olaparib may increase the exposure to substrates of CYP3A4,', 'OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K.', 'Based on limited in vitro data, olaparib may reduce the exposure to substrates of 2B6.', 'The efficacy of hormonal contraceptives may be reduced if co administered with olaparib.', 'Caution should therefore be observed if substrates of these isoenzymes or transporter proteins', 'are co-administered.', 'Examples of substrates include:', 'CYP3A4 - hormonal contraceptive, simvastatin, cisapride, cyclosporine, ergot', 'alkaloids, fentanyl, pimozide, sirolimus, tacrolimus and quetiapine', 'CYP1A2 - duloxetine, melatonin', 'CYP2B6 - bupropion, efavirenz', 'OATP1B1 - bosentan, glibenclamide, repaglinide, statins and valsartan', 'OCT1, MATE1, MATE2K - metformin', 'OCT2 - serum creatinine', 'OAT3 -furosemide, methotrexate', 'Anticoagulant Therapy', 'Patients who are taking warfarin are not permitted to enroll in the study. Subcutaneous heparin', 'and low molecular weight heparin are permitted. Patients that can be safely transitioned to', 'heparin will be permitted to enroll.', 'Anti-emetics/Anti-diarrheals', 'If a patient develops nausea, vomiting and / or diarrhea, then these symptoms should be', 'reported as AEs (see section 6.2) and appropriate treatment of the event given.', 'Palliative radiotherapy', 'Palliative radiotherapy may be used for the treatment of pain at the site of bony metastases', 'that were present at baseline, provided the investigator does not feel that these are indicative', 'of clinical disease progression during the study period. Study treatment should be', 'discontinued for a minimum of 3 days before a patient undergoes therapeutic palliative', 'radiation treatment. Study treatment should be restarted within 4 weeks as long as any bone', 'marrow toxicity has recovered.', 'Administration of other anti-cancer agents', 'Patients must not receive any other concurrent anti-cancer therapy, including investigational', 'agents, while on study treatment. Patients may continue the use of bisphosphonates or', '68(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}